
Sign up to save your podcasts
Or
It's estimated only one percent of medical research spending globally goes toward female-specific conditions that aren't related to cancer. But even as underfunding of women's health persists -- companies focused on women's health are innovating. Dr. Sara Naseri is working to reframe menstrual blood as a diagnostic tool rather than waste, with her company called Qvin. It received FDA clearance in January of this year for a new kind of blood test: a diagnostic menstrual pad.
Guests: Dr. Sara Naseri, CEO and co-founder of Qvin; Axios' Adriel Bettelheim
Credits: 1 big thing is produced by Niala Boodhoo, Alexandra Botti, and Jay Cowit. Music is composed by Alex Sugiura and Jay Cowit. You can reach us at [email protected]. You can send questions, comments and story ideas as a text or voice memo to Niala at 202-918-4893.
4.4
20222,022 ratings
It's estimated only one percent of medical research spending globally goes toward female-specific conditions that aren't related to cancer. But even as underfunding of women's health persists -- companies focused on women's health are innovating. Dr. Sara Naseri is working to reframe menstrual blood as a diagnostic tool rather than waste, with her company called Qvin. It received FDA clearance in January of this year for a new kind of blood test: a diagnostic menstrual pad.
Guests: Dr. Sara Naseri, CEO and co-founder of Qvin; Axios' Adriel Bettelheim
Credits: 1 big thing is produced by Niala Boodhoo, Alexandra Botti, and Jay Cowit. Music is composed by Alex Sugiura and Jay Cowit. You can reach us at [email protected]. You can send questions, comments and story ideas as a text or voice memo to Niala at 202-918-4893.
14,210 Listeners
37,825 Listeners
110,854 Listeners
55,906 Listeners
2,273 Listeners
10,125 Listeners
1,310 Listeners
2,398 Listeners
5,418 Listeners
5,950 Listeners
6,447 Listeners
5,995 Listeners
4,365 Listeners
1,486 Listeners
506 Listeners
1,095 Listeners